Providing information to the drug discovery sector

LeadDiscovery was founded in 1998 by life scientists to expedite drug discovery and pharmaceutical development. Based on a solid background of experience from within the pharmaceutical research and development sector our aim is to help companies optimize drug discovery and product pipelines through the identification of breaking research and the in depth and expert evaluation of selected therapeutic areas.

At the same time we provide a showcase for pharmaceutical, biotechnology and academic organizations wishing to increase the exposure of their research to the drug development community.

We support the drug discovery and pharmaceutical development community through three key services: DailyUpdates, UpdatesPlus and PharmaReports

DailyUpdates Launched in 2002 this popular e-mail alert service delivers information on breaking research, new clinical trials, drug development news and recently published market research and pipeline analysis reports. Today's headlines are below. Registration to receive the service is available here
UpdatesPlus Developed in 2007 as an extension of DailyUpdates, UpdatesPlus provides a monthly in depth analysis of breaking research and development activity in high profile therapeutic areas. Further details can be found here
PharmaReports We offer a wide range of in depth pharmaceutical reports. Our reports include market research reports and pipeline analyses. You can search our entire portfolio using LeadDiscovery's search engine. Alternatively as we are one of the few information providers that has extensive research and development experience we occupy a unique position of being able to source reports that accurately meet your needs. If we don't have a report that fits your requirements we can produce one through our pharmaceutical consultancy services.

Drug Development News: HUMAN GENOME SCIENCES COMPLETES ENROLLMENT IN SECOND PHASE 3 LYMPHOSTAT-B TRIAL

Headlined Journal Article: T40214/PEI complex: A potent therapeutics for prostate cancer that targets STAT3 signaling.

Clinical Trials: A Phase 1/2, Multi-Center, Open-Label, Dose-Escalation Study of HuLuc63 (Humanized Anti CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. (HuLuc63-1702)

Today’s Featured Pharmaceutical Report: Neuronal Nicotinic Receptors - July 2008

Pharmaceutical Training Courses and Meetings: No current events.

LeadDiscovery recommends ClusterMed for faster discovery and automatic organization of PubMed results into categories

PharmaReports: LeadDiscovery offers in depth pharmaceutical reports on selected areas of the pharmaceutical and biotech sector. For a full list of our featured market research reports and pipeline analyses click here